Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
NM

NASDAQ · NMTC

NeuroOne Medical Technologies Corporation

Healthcare · Medical - Devices

$0.93

Down-$0.04 (-4.39%)

Updated Nov 1, 2026, 10:49 AM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
29.33M
P/E ratio
-5.35
Dividend yield
0.00%
52-week range
$0.70 – $5.40
Volume
33.83K
Avg. volume
334.87K

Price performance · NMTC

NMTC price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

NMTC closed at $0.93 after 20 trading sessions, down 16.84% for the selected period.

Last close
$0.93
Period change
-16.84%
Period low
$0.80
Period high
$1.13
Daily close
View OHLC price history
NMTC OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$0.97$1.0188$0.87$0.927233.83K
Oct 29, 2026$0.89$1.04$0.861$0.969866.81K
Oct 28, 2026$0.867$0.93$0.8499$0.858535.8K
Oct 27, 2026$0.804$0.8574$0.804$0.849939.1K
Oct 26, 2026$0.92$0.92$0.7719$0.803943.61K
Oct 23, 2026$0.99$1.00$0.875$0.919372.04K
Oct 22, 2026$0.91$1.05$0.8901$0.98491.5K
Oct 21, 2026$0.97$0.97$0.9113$0.911339.63K
Oct 20, 2026$1.03$1.03$0.9649$0.983835.13K
Oct 19, 2026$0.9657$1.0396$0.9501$1.0016.57K
Oct 16, 2026$1.03$1.05$0.95$0.9614104.22K
Oct 15, 2026$1.05$1.09$1.01$1.04169.05K
Oct 14, 2026$1.09$1.09$1.06$1.0657.5K
Oct 13, 2026$1.08$1.14$1.0504$1.10108.37K
Oct 12, 2026$1.10$1.11$1.05$1.07539.71K
Oct 9, 2026$1.07$1.14$1.04$1.1280.15K
Oct 8, 2026$1.09$1.1157$1.07$1.08315.26K
Oct 7, 2026$1.13$1.155$1.09$1.11116.06K
Oct 6, 2026$1.13$1.17$1.10$1.13118.97K
Oct 5, 2026$1.18$1.35$1.10$1.1151M

Latest NMTC news

The latest Smart Investors Daily articles mentioning NMTC.

Stock researchCompany · Overview

NMTC research

Overview

Company profile and research snapshot.

Company profile

NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$3.00
Implied upside
—
Analysts
—
NMTC recent ratings
DateFirmRatingTarget
Aug 14, 2026Maxim GroupBuy—
May 13, 2026Ladenburg ThalmannBuy—
Mar 2, 2026Jones TradingBuy—
Sep 9, 2025Maxim GroupBuy—
May 5, 2025Ladenburg ThalmannBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 29, 2026

NeuroOne® Announces Peer-Reviewed Publication of Initial Clinical Experience with OneRF® Trigeminal Nerve Ablation System

Study Reports Immediate Pain Freedom in 14 of 15 Patients; all Patients Achieved Favorable Pain Outcomes at a Mean Six-Month Follow-Up Multi-Contact Probe Technology Enabled Mapping and Treatment of Trigeminal Nerve Distributions without Repeated Probe Repositioning EDEN PRAIRIE, Minn., Oct. 29, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on the surgical diagnosis and treatment of neurologic

Yahoo · Oct 27, 2026

NeuroOne Featured in New York Post on OneRF® Patient’s Remarkable Journey to Overcome Debilitating Facial Pain

NeuroOne’s FDA 510(k)-Cleared OneRF Trigeminal Nerve Ablation System Offers Hope for Patients Suffering from Trigeminal Neuralgia EDEN PRAIRIE, Minn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today highlighted a feature article published in the New York Post showcasing the successful treatment of a

Yahoo · Oct 22, 2026

NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Company's Research Program

Major Commercial Milestone Represents Important Step Toward Potential Long-Term Collaborations with Global Pharmaceutical Companies EDEN PRAIRIE, Minn., Oct. 22, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, today announced that it has secured its first pharmaceutical industry purchase order for the StereoCED™ Dr

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By